fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63   |   64   |   65   
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2006-02-10 MAT BioPharma (France)
Institut de Recherche Pierre Fabre (France)
monoclonal antibodies / cancer R&D
See details
2006-02-08 NPS Pharmaceuticals (USA)
AstraZeneca (UK)
drugs targeting metabotropic glutamate receptors / CNS diseases, gastro-intestinal pathologies R&D
commercialization/ distribution
See details
2006-02-08 G2Therapies (Australia)
Novo Nordisk (Denmark)
anti-inflammatories based on anti-C5a receptor antibodies / rheumatoid arthritis and other auto-immune diseases R&D
manufacturing
commercialization/ distribution
See details
2006-02-07 Hybrigenics (France)
The Universities of Leuven and Ghent (both Belgium)
 
inecalcitol in all its therapeutic indications / Two development axes for this vitamin D analogue: (i) oncology and notably hormone therapy- refractory prostate cancer, (ii) psoriasis and hyperparathyroidism, in collaboration with Theramex. licensing
See details
2006-01-27 Biomira (Canada)
Merck KGaA (Germany)
Stimuvax (liposomal vaccine BLP25) / non-small-cell lung cancer commercialization/ distribution
development
See details
2006-01-23 Biovitrum (Sweden)
Syntonix (USA)
recombinant factor IX / haemophilia B commercialization/ distribution
development
See details
2006-01-18 Evotec (Germany)
Boehringer Ingelheim (Germany)
therapeutic compounds acting on G-protein-coupled receptors /  CNS, inflammation, cardiometabolic and respiratory diseases, oncology R&D
other
See details
2006-01-16 BioFocus DPI/Galapagos (Belgium)
Boehringer Ingelheim (Germany)
drug targets / autoimmune diseases R&D
See details
2006-01-15 Nuvelo (USA)
Bayer (Germany)
alfimeprase (an antithrombotic) / acute peripheral arterial occlusion, stroke commercialization/ distribution
development
See details
2006-01-09 CancerVax (USA)
Micromet (Germany)
/ oncology, autoimmune and inflammatory diseases other
See details
2006-01-01 Biovitrum (Sweden)
Symphogen (Denmark)
 
Sym001 (Symphogen's combination of 25 recombinant anti-rhesus D antibodies) / idiopathic thrombocytopenic purpura and neonatal haemolytic disease commercialization/ distribution
development
See details
[<<]      «      55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63   |   64   |   65